Citations

Showing 10 of 108094 citations.

Surgical Observations on Visits to the Far and Middle East, Part II
Walters, Waltman

Mayo Clinic

Military Medicine | April 30, 2018 | Volume: 127 | Issue: 12 | Pages: 1009-1019

10.1093/milmed/127.12.1009 Get It

Alpha‐1 antitrypsin deficiency panniculitis: clinical and pathologic characteristics of 10 cases
Johnson, Emma F. , Tolkachjov, Stanislav N. , Gibson, Lawrence E.

Mayo Clinic

International Journal of Dermatology | April 30, 2018 | Volume: 57 | Issue: 8 | Pages: 952-958

10.1111/ijd.14012 | PMID 29707779 Get It

SummaryBackgroundAlpha‐1 antitrypsin deficiency (AATD) may be associated with liver and lung disease and rarely causes panniculitis.ObjectiveWe evaluated the clinicopathologic and laboratory findings of AATD panniculitis in 10 patients.MethodsWe conducted a retrospective review of all cases of AATD panniculitis at Mayo Clinic, Rochester, MN, from 1989 to 2016.ResultsTen patients with AATD panniculitis were included. Seven of ten were women. Clinical lesions were most commonly nodular (100%), erythematous (90%), ulcerated (90%), and painful (90%) subcutaneous nodules and plaques. Extracutaneous associations were rare. PiZZ phenotype was most commonly identified (50%). Histopathologically, lobular panniculitis (80%) with associated septal involvement (60%) and a predominant neutrophilic infiltrate (100%) were most common. Treatments varied; dapsone and alpha‐1 proteinase inhibitor infusions were each used in five (50%) patients, respectively. In patients with greater than 6‐month follow‐up (n = 4), one patient continued to have disease activity despite treatment.ConclusionAATD panniculitis should be considered in the differential for a painful, ulcerative panniculitis with a predominantly neutrophilic histopathologic infiltrate. Diagnosis can be made with clinicopathologic correlation and genetic and laboratory evaluations. Serum AAT level and phenotype assists in diagnosing patients with suspected AATD panniculitis.
Surgical Observations on Visits to the Far and Middle East (In Three Parts)
Walters, Waltman

Mayo Clinic

Military Medicine | April 30, 2018 | Volume: 127 | Issue: 11 | Pages: 908-923

10.1093/milmed/127.11.908 Get It

Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation
Chakraborty, Rajshekhar , Muchtar, Eli , Kumar, Shaji , Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Lacy, Martha Q. , Warsame, Rahma , Kourelis, Taxiarchis , Kumar, Shaji K , Buadi, Francis K. , Gonsalves, Wilson , Muchtar, E , Chakraborty, Rajshekhar , Dingli, David , Dispenzieri, Angela , Hogan, William J. , Leung, Nelson , Gonsalves, Wilson I. , Gertz, Morie A.

Mayo Clinic

British Journal of Haematology | April 30, 2018 | Volume: 182 | Issue: 1 | Pages: 71-77

10.1111/bjh.15244 | PMID 29707759 Get It

SummaryThe optimal duration of induction therapy (IT) in transplant‐eligible multiple myeloma (MM) patients in not well defined, resulting in a wide variation in clinical practice. The objective of our study was to determine whether the duration of IT in patients undergoing upfront autologous stem cell transplantation (ASCT) has an impact on progression‐free survival (PFS) in the era of proteasome inhibitors and immunomodulatory drugs. A total of 596 patients who underwent ASCT at Mayo Clinic between 2007 and 2014 were included. The patients were divided into two cohorts based on the duration of IT: IT ≤ 4 and IT > 4 months. At a median follow‐up of 54·5 months from ASCT, the median PFS in the IT ≤ 4 group was 28 months [95% confidence interval (CI), 25–33], compared to 26 months in the IT > 4 group (95% CI, 24–31) [P = 0·605]. There was no significant difference in overall survival (OS) in the two groups (P = 0·904). The lack of impact of IT duration on PFS and OS was consistent in subgroups with high‐risk features at diagnosis (International Staging System III or high‐risk cytogenetics) and different depths of pre‐transplant response [≥very good partial response (VGPR) and <VGPR]. In conclusion, prolonging the duration of IT beyond 4 months does not impact survival in patients with newly diagnosed MM who complete a single line of IT followed by consolidation with ASCT.
Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes?
Paradise, Brooke D., Barham, Whitney , Fernández-Zapico, Martín E.

Mayo Clinic

Cancers | April 30, 2018 | Volume: 10 | Issue: 5 | Pages: 128

10.3390/cancers10050128 | PMID 29710783 Get It

Pancreatic cancer has one of the highest mortality rates among all types of cancers. The disease is highly aggressive and typically diagnosed in late stage making it difficult to treat. Currently, the vast majority of therapeutic regimens have only modest curative effects, and most of them are in the surgical/neo-adjuvant setting. There is a great need for new and more effective treatment strategies in common clinical practice. Previously, pathogenesis of pancreatic cancer was attributed solely to genetic mutations; however, recent advancements in the field have demonstrated that aberrant activation of epigenetic pathways contributes significantly to the pathogenesis of the disease. The identification of these aberrant activated epigenetic pathways has revealed enticing targets for the use of epigenetic inhibitors to mitigate the phenotypic changes driven by these cascades. These pathways have been found to be responsible for overactivation of growth signaling pathways and silencing of tumor suppressors and other cell cycle checkpoints. Furthermore, new miRNA signatures have been uncovered in pancreatic ductal adenocarcinoma (PDAC) patients, further widening the window for therapeutic opportunity. There has been success in preclinical settings using both epigenetic inhibitors as well as miRNAs to slow disease progression and eliminate diseased tissues. In addition to their utility as anti-proliferative agents, the pharmacological inhibitors that target epigenetic regulators (referred to here as readers, writers, and erasers for their ability to recognize, deposit, and remove post-translational modifications) have the potential to reconfigure the epigenetic landscape of diseased cells and disrupt the cancerous phenotype. The potential to “reprogram” cancer cells to revert them to a healthy state presents great promise and merits further investigation.
The Doctors Mayo and Their Military Medical Activities
Walters, Waltman

Mayo Clinic

Military Medicine | April 30, 2018 | Volume: 130 | Issue: 4 | Pages: 331-341

10.1093/milmed/130.4.331 Get It

A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya
Binnicker, Matthew J. , Campbell, Sheldon , Chapin, Kimberle C. , Gilligan, Peter H., Gonzalez, Mark D. , Jerris, Robert C. , Kehl, Sue C., Patel, Robin , Pritt, Bobbi S. , Richter, Sandra S. , Robinson-Dunn, Barbara, Schwartzman, Joseph D., Snyder, James W. , Telford, Sam R. , Theel, Elitza S. , Thomson, Richard B., Weinstein, Melvin P., Yao, Joseph D. , Patel, Robin , Pritt, Bobbi S , Miller, J. Michael , Carroll, Karen C.

Mayo Clinic

Clinical Infectious Diseases | April 30, 2018 | Volume: 67 | Issue: 6 | Pages: e1-e94

10.1093/cid/ciy381 | PMID 29955859 Get It

Abstract The critical nature of the microbiology laboratory in infectious disease diagnosis calls for a close, positive working relationship between the physician/advanced practice provider and the microbiologists who provide enormous value to the healthcare team. This document, developed by experts in laboratory and adult and pediatric clinical medicine, provides information on which tests are valuable and in which contexts, and on tests that add little or no value for diagnostic decisions. This document presents a system-based approach rather than specimen-based approach, and includes bloodstream and cardiovascular system infections, central nervous system infections, ocular infections, soft tissue infections of the head and neck, upper and lower respiratory infections, infections of the gastrointestinal tract, intra-abdominal infections, bone and joint infections, urinary tract infections, genital infections, and other skin and soft tissue infections; or into etiologic agent groups, including arthropod-borne infections, viral syndromes, and blood and tissue parasite infections. Each section contains introductory concepts, a summary of key points, and detailed tables that list suspected agents; the most reliable tests to order; the samples (and volumes) to collect in order of preference; specimen transport devices, procedures, times, and temperatures; and detailed notes on specific issues regarding the test methods, such as when tests are likely to require a specialized laboratory or have prolonged turnaround times. In addition, the pediatric needs of specimen management are also emphasized. There is intentional redundancy among the tables and sections, as many agents and assay choices overlap. The document is intended to serve as a guidance for physicians in choosing tests that will aid them to quickly and accurately diagnose infectious diseases in their patients.
Three‐dimensional porous poly(propylene fumarate)‐co‐poly(lactic‐co‐glycolic acid) scaffolds for tissue engineering
Wu, Wei , Liu, Xifeng , Zhou, Zifei , Miller, A. Lee , Lu, Lichun , Miller, Alan Lee

Mayo Clinic

Journal of Biomedical Materials Research Part A | April 30, 2018 | Volume: 106 | Issue: 9 | Pages: 2507-2517

10.1002/jbm.a.36446 | PMID 29707898 Get It

AbstractThree‐dimensional structural scaffolds have played an important role in tissue engineering, especially broad applications in areas such as regenerative medicine. We have developed novel biodegradable porous poly(propylene fumarate)‐co‐poly(lactic‐co‐glycolic acid) (PPF‐co‐PLGA) scaffolds using thermally induced phase separation, and determined the effects of critical parameters such as copolymer concentration (6, 8, and 10 wt %) and the binary solvent ratio of dioxane:water (78/22, 80/20, 82/18 wt/wt %) on the fabrication process. The cloud‐point temperatures of PPF‐co‐PLGA changed in parallel with increasing copolymer concentration, but inversely with increasing dioxane content. The compressive moduli of the scaffolds increased with greater weight composition and dioxane:water ratio. Scaffolds formed using high copolymer concentrations and solvent ratios exhibited preferable biomineralization. All samples showed biodegradation capability in both accelerated solution and phosphate‐buffered saline (PBS). Cell toxicity testing indicated that the scaffolds had good biocompatibility with bone and nerve cells, which adhered well to the scaffolds. Variations in the copolymer concentration and solvent ratio exercised a remarkable influence on morphology, mechanical properties, biomineralization, and biodegradation, but not on the cell viability and adhesion of the cross‐linked scaffolds. An 8 to 10 wt % solute concentration and 80/20 to 82/18 wt/wt dioxane:water ratio were the optimum parameters for scaffold fabrication. PPF‐co‐PLGA scaffolds thus possess several promising prospects for tissue engineering applications. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A:2507–2517, 2018.
The Impact of Pazopanib on the Cardiovascular System
Justice, Cody N. , Derbala, Mohamed H. , Baich, Tesla M., Kempton, Amber, Guo, Aaron , Ho, Thai H. , Smith, Sakima A. , Ho, Thai

Mayo Clinic

Journal of Cardiovascular Pharmacology and Therapeutics | April 30, 2018 | Volume: 23 | Issue: 5 | Pages: 387-398

10.1177/1074248418769612 | PMID 29706106 Get It

Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma. However, its clinical efficacy is limited by its cardiovascular side effects. Pazopanib and other vascular endothelial growth factor receptor tyrosine kinase inhibitors have been associated with the development of hypertension, QT interval prolongation, and other cardiovascular events; however, these mechanisms are largely unknown. Gaining a deeper understanding of these mechanisms is essential for the development of appropriate surveillance strategies and possible diagnostic biomarkers to allow us to monitor patients and modulate therapy prior to significant cardiac insult. This approach will be vital in keeping patients on these life-saving therapies and may be applicable to other tyrosine kinase inhibitors as well. In this review, we provide a comprehensive overview of the preclinical and clinical side effects of pazopanib with a focus on the mechanisms responsible for its toxicity to the cardiovascular system.
Inter‐laboratory comparison of channelized hotelling observer computation
Ba, Alexandre, Abbey, Craig K. , Baek, Jongduk , Han, Minah , Balta, Christiana, Brankov, Jovan G. , Massanés, Francesc, Gifford, Howard C. , Veldkamp, Wouter J. H. , Petrov, Dimitar, Marshall, Nicholas , Samuelson, F. W. , Zeng, Rongping , Solomon, Justin B., Samei, Ehsan , Timberg, Pontus, Förnvik, Hannie, Reiser, Ingrid , Yu, Lifeng , Gong, Hao , Bochud, François , Bouwman, Ramona W. , Giron, Irene Hernandez , Solomon, Justin , Yu, Lifeng , Reiser, Ingrid

Mayo Clinic

Medical Physics | April 28, 2018 | Volume: 45 | Issue: 7 | Pages: 3019-3030

10.1002/mp.12940 | PMID 29704868 Get It

PurposeThe task‐based assessment of image quality using model observers is increasingly used for the assessment of different imaging modalities. However, the performance computation of model observers needs standardization as well as a well‐established trust in its implementation methodology and uncertainty estimation. The purpose of this work was to determine the degree of equivalence of the channelized Hotelling observer performance and uncertainty estimation using an intercomparison exercise.Materials and MethodsImage samples to estimate model observer performance for detection tasks were generated from two‐dimensional CT image slices of a uniform water phantom. A common set of images was sent to participating laboratories to perform and document the following tasks: (a) estimate the detectability index of a well‐defined CHO and its uncertainty in three conditions involving different sized targets all at the same dose, and (b) apply this CHO to an image set where ground truth was unknown to participants (lower image dose). In addition, and on an optional basis, we asked the participating laboratories to (c) estimate the performance of real human observers from a psychophysical experiment of their choice. Each of the 13 participating laboratories was confidentially assigned a participant number and image sets could be downloaded through a secure server. Results were distributed with each participant recognizable by its number and then each laboratory was able to modify their results with justification as model observer calculation are not yet a routine and potentially error prone.ResultsDetectability index increased with signal size for all participants and was very consistent for 6 mm sized target while showing higher variability for 8 and 10 mm sized target. There was one order of magnitude between the lowest and the largest uncertainty estimation.ConclusionsThis intercomparison helped define the state of the art of model observer performance computation and with thirteen participants, reflects openness and trust within the medical imaging community. The performance of a CHO with explicitly defined channels and a relatively large number of test images was consistently estimated by all participants. In contrast, the paper demonstrates that there is no agreement on estimating the variance of detectability in the training and testing setting.